Article
18 February 2026 - by Katherine M. Holcomb, Jake K. Klaisner, Dan Simenc
Medicare drug price negotiation: With the first cycle where Part B drugs are eligible to be selected, the implications extend far beyond simple price reductions.
Article
12 January 2026 - by Jake K. Klaisner, Katherine M. Holcomb, Dan Simenc
Deeper discounts in the latest round of negotiated prices for Medicare Part D drugs may indicate how future negotiations will play out.
Article
17 December 2025 - by Jake K. Klaisner, Kali Schweitzer, Pepper Huang
We analyze hospital price transparency data to show variations in reimbursement for autoimmune drugs, with implications for patient access and affordability.
Article
24 October 2025 - by Dylan Collin, Jeremy Hamilton, Jake K. Klaisner
With the 2026 Medicare Advantage and Part D bid cycle affecting costs and revenues, we highlight key changes to the individual prescription drug plan market.
Article
30 July 2025 - by Katherine M. Holcomb, Jake K. Klaisner, Philip Nelson, Ivanna Ulin
340B disproportionate share hospitals consistently have higher drug costs across commercial and Medicare plans, according to our latest study on this population.
Article
07 February 2025 - by Dan Simenc, Jake K. Klaisner, Katherine M. Holcomb
We provide some insights on Medicare price negotiation's year-two selection, which expands to new therapeutic areas.
Article
24 October 2024 - by Jake K. Klaisner, Madeleine Feller
Analyzing data from the Centers for Medicare and Medicaid Services, we highlight key changes in the prescription drug plan market for 2025.
Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Feller, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.
Article
10 June 2024 - by Jake K. Klaisner, AJ Ally, Briana Botros, Kristin Niakan, Ryan LeRoy
We examine the impact of anti-obesity medication coverage in the Medicaid and commercial markets, as drugs such as Wegovy and Zepbound take off.
Article
06 March 2024 - by Madeleine Feller, Jake K. Klaisner, Ali M. Heinrich, Katherine M. Holcomb, Melanie K. Kuester
How might requiring Part D coverage for anti-obesity medications affect Medicare program costs?